glp 1 agonists reduce inflammation GLP-1 Drugs: For Multiple Chronic Conditions The Therapeutic Potential of GLP-1

For more information, contact us or schedule an appointment online

FDA labeling states that GLP-1 receptor agonists are not recommended for patients with severe gastroparesis

The future landscape: what comes next The comparison between tirzepatide and retatrutide is a snapshot of a rapidly evolving field

Back Thorens, B, Hodson, DJ (2024) Building the glucagon-like peptide-1 receptor brick by brick: Revisiting a 1993 Diabetes Classic by Thorens et al, Diabetes, 73, 1027-31

Pharmacodynamics, pharmacokinetics, safety and tolerability of the novel dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 agonist RG7697 after single subcutaneous administration in healthy subjects